NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS

$564M01FY2000RRNIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 30232528 Paper 28296798 Paper 27677166 Paper 27238356 Paper 27045376 Paper 27018579 Paper 26595542 Paper 26554398 Paper 26507723 Paper 26372276 Paper 26362106 Paper 25513818 Paper 25500725 Paper 25465205 Paper 25409471 Paper 24926019 Paper 24419071 Paper 24418810 Paper 24406073 Paper 24367482 Paper 24260137 Paper 24136113 Paper 24105030 Paper 23904290 Paper 23901097 Paper 23687224 Paper 23649425 Paper 23576116 Paper 23460748 Paper 23349510 Paper 23315317 Paper 23287403 Paper 23267855 Paper 23255060 Paper 23242158 Paper 23130122 Paper 23086116 Paper 23075914 Paper 22944874 Paper 22878421 Paper 22874518 Paper 22781217 Paper 22319043 Paper 22169125 Paper 22073156 Paper 22034200 Paper 21926283 Paper 21897333 Paper 21875343 Paper 21813792 Paper 21767228 Paper 21743843 Paper 21641117 Paper 21572308 Paper 21508633 Paper 21437932 Paper 21350366 Paper 21310810 Paper 21164182 Paper 21157476 Paper 21075899 Paper 20958328 Paper 20817416 Paper 20709438 Paper 20671544 Paper 20651585 Paper 20616323 Paper 20610601 Paper 20581689 Paper 20561082 Paper 20539305 Paper 20512045 Paper 20502316 Paper 20490909 Paper 20447913 Paper 20442796 Paper 20400410 Paper 20386106 Paper 20356567 Paper 20309612 Paper 20173677 Paper 20056635 Paper 20044858 Paper 20009918 Paper 19933410 Paper 19904206 Paper 19890203 Paper 19877800 Paper 19845473 Paper 19821723 Paper 19803778 Paper 19773739 Paper 19741514 Paper 19738484 Paper 19680131 Paper 19637058 Paper 19558011 Paper 19537956 Paper 19537231 Paper 19525206

Abstract

This is a randomized, double-blind, placebo-controlled study in patients with HIV-associated weight loss. Eligible individuals will receive nandrolone decanoate or placebo by weekly intramuscular injection for 12 weeks. All patients who successfully complete a 12-week placebo-controlled phase will be eligible to receive open-label nandrolone for an additional 12 weeks. Response to treatment will be evaluated by measuring body weight and composition, functional performance, quality of life, and energy and macronutrient intake. Safety, HIV disease progression, and immunologic status will be closely monitored throughout the study.

View original record on NIH RePORTER →